Transcenta Holding Ltd
Company Profile
Business description
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capacities in discovery, research, development, manufacturing, and business development. It is developing approximately fifteen therapeutic antibody molecules for oncology and selected non-oncology indications, including bone and kidney disorders. The company's drug development pipeline includes Osemitamab (TST001), TST002 (Blosozumab), TST003, TST006, MSB2311, MSB0254, TST808, and others to treat various oncology and non-oncology complications in different ways. Geographically, the company operates in China (the PRC), which is its key revenue market, and the United States of America.
Contact
218 Xinghu Street
B6-501, Biobay
Suzhou215123
CHNT: +86 51267079200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
171
Stocks News & Analysis
stocks
Procter & Gamble earnings: Frigid sales and margins don’t suggest cracks in its standing
stocks
Our view on Santos after production is ramped up
stocks
GE Aerospace earnings: No good deed goes unpunished
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.90 | 15.70 | 0.17% |
| CAC 40 | 8,128.32 | 20.57 | -0.25% |
| DAX 40 | 24,882.40 | 25.93 | 0.10% |
| Dow JONES (US) | 49,384.01 | 306.78 | 0.63% |
| FTSE 100 | 10,160.88 | 10.83 | 0.11% |
| HKSE | 26,749.51 | 119.55 | 0.45% |
| NASDAQ | 23,436.02 | 211.20 | 0.91% |
| Nikkei 225 | 53,846.87 | 157.98 | 0.29% |
| NZX 50 Index | 13,448.24 | 108.63 | -0.80% |
| S&P 500 | 6,913.35 | 37.73 | 0.55% |
| S&P/ASX 200 | 8,860.10 | 15.00 | 0.17% |
| SSE Composite Index | 4,136.16 | 13.59 | 0.33% |